HC Wainwright Issues Pessimistic Estimate for EYPT Earnings

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – HC Wainwright decreased their FY2024 earnings per share estimates for shares of EyePoint Pharmaceuticals in a research note issued to investors on Monday, November 11th. HC Wainwright analyst Y. Chen now expects that the company will earn ($2.15) per share for the year, down from their prior estimate of ($2.09). HC Wainwright has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for EyePoint Pharmaceuticals’ current full-year earnings is ($2.21) per share. HC Wainwright also issued estimates for EyePoint Pharmaceuticals’ Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.59) EPS, Q4 2025 earnings at ($0.59) EPS and FY2025 earnings at ($2.06) EPS.

Other research analysts have also issued research reports about the company. StockNews.com upgraded EyePoint Pharmaceuticals to a “sell” rating in a report on Saturday, September 21st. Jefferies Financial Group started coverage on shares of EyePoint Pharmaceuticals in a research note on Wednesday, August 28th. They set a “buy” rating and a $15.00 price objective for the company. Robert W. Baird lowered their target price on EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating on the stock in a report on Monday, November 11th. Scotiabank started coverage on EyePoint Pharmaceuticals in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $18.00 price objective on the stock. Finally, JPMorgan Chase & Co. dropped their target price on EyePoint Pharmaceuticals from $32.00 to $29.00 and set an “overweight” rating for the company in a report on Tuesday, August 13th. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $28.00.

EyePoint Pharmaceuticals Trading Down 12.6 %

NASDAQ:EYPT opened at $9.17 on Thursday. The firm has a market cap of $490.78 million, a P/E ratio of -4.59 and a beta of 1.50. The stock has a 50 day moving average of $9.74 and a two-hundred day moving average of $9.85. EyePoint Pharmaceuticals has a 12 month low of $5.86 and a 12 month high of $30.99.

Hedge Funds Weigh In On EyePoint Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. boosted its position in shares of EyePoint Pharmaceuticals by 44.0% during the first quarter. Ameritas Investment Partners Inc. now owns 3,719 shares of the company’s stock worth $77,000 after buying an additional 1,136 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in EyePoint Pharmaceuticals by 68.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company’s stock valued at $82,000 after acquiring an additional 4,172 shares during the period. Greenwich Wealth Management LLC grew its position in EyePoint Pharmaceuticals by 8.3% in the 3rd quarter. Greenwich Wealth Management LLC now owns 11,700 shares of the company’s stock valued at $93,000 after acquiring an additional 900 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in EyePoint Pharmaceuticals by 271.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,888 shares of the company’s stock worth $95,000 after purchasing an additional 7,953 shares during the period. Finally, Cyndeo Wealth Partners LLC acquired a new stake in shares of EyePoint Pharmaceuticals during the third quarter worth about $100,000. Hedge funds and other institutional investors own 99.41% of the company’s stock.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.